Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously

Clinical Cancer Research

Volumn 9, Issue 10 I, 2003, Pages 3578-3588

  Kelly, Wm Kevin ^a,c   Richon, Victoria M ^b   O'Connor, Owen ^a   Curley, Tracy ^a   MacGregor Curtelli, Barbara ^a   Tong, William ^a   Klang, Mark ^a   Schwartz, Lawrence ^a   Richardson, Stacie ^a   Rosa, Eddie ^b   Drobnjak, Marija ^a   Cordon Cordo, Carlos ^a   Chiao, Judy H ^b   Rifkind, Richard ^a   Marks, Paul A ^a   Scher, Howard ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Aton Pharma Inc   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; HISTONE DEACETYLASE INHIBITOR; VORINOSTAT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLADDER TUMOR; BONE MARROW TOXICITY; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LYMPHOMA; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TUMOR BIOPSY; TUMOR REGRESSION; VOMITING;

ACETYLATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC NEOPLASMS; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SKIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 12444321545     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Marks, P., Rifkind, R., Richon, V., Breslow, R., Miller, T., and Kelly, W. K. Histone deacetylase and cancer: causes and therapies. Nat. Rev., 1: 194-202, 2001.
2. Warrell, R. P., Jr., He, L. Z., Richon, V., Calleja, E., and Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst., (Bethesda) 90: 1621-1625, 1998.
3. Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., and Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA, 95: 3003-3007, 1998.
4. Kelly, W. K., O'Connor, O., and Marks, P. Histone deacetylase inhibitors: from target to clinical trials. EOID, 11: 1695-1713, 2002.
5. Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., and Marks, P. A. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl. Acad. Sci. USA, 93: 5705-5708, 1996.
6. Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon-Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., and Richon, V. M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer in vitro and in vivo. Cancer Res., 60: 5165-5170, 2000.
7. Cohen, L. A., Amin, S., Marks, P. A., Rifkind, R. A., Desai, D., and Richon, V. M. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res., 19: 4999-5006, 1999.
8. Scher, H. I., Mazumdar, M., and Kelly, W. K. Clinical trials in relapsed prostate cancer: defining the target. J. Natl. Cancer Inst. (Bethesda), 88: 1623-1634, 1996.
9. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
10. Yoshida, M., Kijima, M., Akita, M., and Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem., 265: 17174-9, 1990.
11. Rowinsky, E., and Donehower, R. Vinca alkaloids and epipodphyllotoxins. In: M. Perry (ed.), The Chemotherapy Source Book, Vol. 1, pp. 359-383. Baltimore: Williams & Wilkins, 1992.
12. Carducci, M., Gilbert, J., Bowling, M., Noe, D., Eisenberger, M., Sinibaldi, V., Zabelina, Y., Chen, T., Grochow, L., and Donehower, R. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res., 7: 3047-3055, 2001.
13. Sandor, V., Bakke, S., Robey, R., Kang, M. H., Blagaskonny, M., Brooks, R., Piekarz, R., Tucker, E., Figg, W. D., Chan, K. K., Goldspiel, B., Sausville, E., Balcerzak, S. P., and Bates, S. E. Phase I trial of a novel antitumor depsipeptide (FR 901228) in patients with refractory neoplasms. Clin. Cancer Res., 8: 718-728, 2002.
14. Gilbert, J., Baker, S. D., Bowling, M. K., Grochow, L., Figg, W. D., Zabelina, Y., Donehower, R. C., and Carducci, M. A. A Phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid malignancies. Clin. Cancer Res., 7: 2292-2300, 2001.
15. Carducci, M., Bowling, M. K., Eisenberger, M., Sinibaldi, V., Chen, T., Noe, D., Grochow, L., and Donehower, R. Phenylbutyrate (PB) for refractory solid tumors: Phase I clinical and pharmacologic evaluation of intravenous and oral PB. Anticancer Res., 17: 3972-3973, 1997.
16. Prakash, S., Foster, B., Meyer, M., Wozniak, A., Heilbrun, L., Flaherty, L., Zalupski, M., Radulovic, L., Valdivieso, M., and LoRusso, P. Chronic administration of CI-994: a Phase I study. Investig. New Drugs, 19: 1-11, 2001.
17. Hockly, E., Richon, V., Woodman, B., Smith, D., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P., Steffan, J., Marsh, J., Thompson, L., Lewis, C., Marks, P., and Bates, G. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's Disease. Proc. Natl. Acad. Sci., USA, 100: 2041-2046, 2003.